Next Article in Journal
Assessment of Hydrochar and Porous Carbon from Tectona Grandis Seeds for Removal of Acridine Dyes
Previous Article in Journal
Dictyopterenes A, B, C, and D from Marine Algae
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 30
Issue 19
10.3390/molecules30193988
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Discovery of Primaquine–Indole Carboxamides with Cancer-Cell-Selective Antiproliferative Activity

by
Benjamin H. Peer
1,†,
Jeremiah O. Olugbami
1,†,
Dipak T. Walunj
1,† and
Adegboyega K. Oyelere
1,2,*
1
School of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA 30332, USA
2
Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr. NW, Atlanta, GA 30332, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2025, 30(19), 3988; https://doi.org/10.3390/molecules30193988
Submission received: 4 September 2025 / Revised: 30 September 2025 / Accepted: 1 October 2025 / Published: 4 October 2025
Browse Figures
Versions Notes

Abstract

Indole carboxylic acids are endogenous tryptophan metabolites that have demonstrated a variety of bioactivities, including anticancer effects. Specifically, indole acetic acid (IAA) elicits anticancer activity when combined with ultraviolet B or reactive oxygen species (ROS) generators. Primaquine (PQ) is an approved drug which elicits antimalarial activity through ROS generation. We investigated the effects of ICA, IAA, PQ, their combination and PQ–indole carboxamide conjugates on the viability of selected cancer cell lines. We identified PQ–indole carboxamide 2 which elicited more potent antiproliferative effects than PQ and ICA/PQ combination. Our data revealed that compound 2 derived a significant part of its antiproliferative effect from ROS generation.

1. Introduction

Metabolism of tryptophan in the human gastrointestinal tract by host and gut microbiota results in the generation of indole and several indole-based acids, including indole-3-carboxylic acid (ICA), indole-3-acetic acid (IAA), and indole-3-propionic acid (IPA) (Figure 1) [1,2,3]. IAA, a plant growth hormone, has been reported to enhance the efficacy of first-line chemotherapies in pancreatic cancer [4]. While IAA is highly tolerated in human body systems, it elicits an independent anticancer activity when combined with UVB or reactive oxygen species (ROS) generators such as horseradish peroxidase and phenothiazinium dyes [5,6,7,8,9]. Horseradish peroxidase-mediated activation of IAA involves oxidative mechanisms that result in toxic metabolites, including endoperoxide and singlet oxygen [6]. Combination treatments of IAA with other relatively benign FDA-approved oxidants and/or ROS inducers, which have demonstrated potential anticancer effects, could have enhanced clinical outcomes.
Primaquine (PQ) (Figure 1) is a commonly used antimalarial drug that kills malarial parasites, possibly due to the generation of ROS through the cycling of its hydroxylated metabolites [10,11,12,13]. PQ has also demonstrated weak anticancer effects, inhibiting the proliferation of cancer cells at high micromolar to millimolar IC50s [14,15,16]. Epidemiologically, there is an inverse correlation between malaria and multiple cancer types [17,18]. Hence, it is likely that the ROS-producing activity of PQ contributes to its anticancer effects. In addition, a variety of other mechanisms, including inhibition of endosomal trafficking and nuclear localization of epidermal growth factor receptor [14] and alleviation of P-glycoprotein-induced tumor resistance to chemotherapy [19,20], have been suggested to contribute to the anticancer activity of PQ.
In this study, we investigated the effects of the combination of IAA and PQ, in the context of standard combination therapy and carboxamide conjugate of primaquine–indole acetic acid (PQ-IAA 1), on the viability of breast (MCF-7, MDA-MB-231, and MDA-MB-453), liver (Hep-G2), and prostate (DU-145 and LNCaP) cancer cell lines along with the Vero normal/control cell line. Although PQ is slightly more potent than PQ-IAA 1 and the IAA/PQ combination in some cell lines, we observed a disparity in the pattern of the antiproliferative effects of PQ, PQ-IAA 1, and the IAA/PQ combination. Informed by this data, we synthesized a cohort of PQ–indole carboxamide conjugates incorporating indole acid analogs (compounds 2–7). Evaluation of the antiproliferative activities of these compounds revealed that PQ–indole-3-carboxamide (PQ-ICA) 2 elicited enhanced potency with a preference for the prostate cancer cell line LNCaP. Subsequently, we synthesized and tested the antiproliferative activities of the enantiomers of 2 (compounds 8 and 10) and 4 (compounds 9 and 11). We surprisingly found that the racemic compounds 2 and 4 outperformed their individual enantiomers. Because the androgen receptor (AR) is vital to the viability of LNCaP cells, we conducted molecular docking analysis of the interaction of the R- and S-enantiomers of the disclosed PQ-indole compounds at the AR ligand binding domain (LBD) [21] and binding function 3 (BF3) sites [22] to obtain evidence for the involvement of AR interaction in their antiproliferative activities. Despite molecular docking predictions, which suggested that these compounds are better accommodated at the AR-LBD (Figure S3; Tables S1 and S2), evaluation of their representative examples in cell-free AR binding assay revealed that these compounds lacked AR-binding affinity (Figure S4). Additionally, we probed for the ROS-inducing effects of compound 2, ICA, PQ, and the ICA/PQ combination in LNCaP cells. Our data revealed that 2 is a much more effective ROS inducer, generating higher levels of ROS in LNCaP cells when compared with hydrogen peroxide, ICA, PQ, and the ICA/PQ combination. Finally, we observed that LNCaP cells were dose-dependently arrested by 2 at both S and G2/M phases. Overall, these results suggest that 2 derived a significant part of its antiproliferative effect from ROS generation. However, the mechanism(s) of ROS generation activity of 2 is yet to be elucidated.

2. Results and Discussion

2.1. Synthesis

The synthesis of the designed PQ–indole carboxamide conjugates 1–6 involved a direct coupling of PQ with the corresponding indole carboxylic acid in dichloromethane (CH2Cl2) using EDCI and a catalytic amount of DMAP. A mild base treatment of compound 6 furnished PQ–indole carboxamide 7 (Scheme 1). The enantiomerically pure PQ–indole carboxamides 8–11 were similarly synthesized from (-)-(R)-primaquine and (+)-(S)-primaquine (Scheme 2). The requisite PQ enantiomers were obtained from the PQ racemate as described by Nanayakkara et al. [23]. The structures of the synthesized compounds were confirmed using 1H NMR, 13C NMR, and HRMS analyses (see Supplementary Materials).

2.2. Antiproliferative Activity of Primaquine–Indole Carboxamide

As single agents, IAA and ICA are not cytotoxic against the tested cell lines up to the maximum tested concentration (100 µM). In contrast, we observed that PQ displayed cell-line-dependent cytotoxic effects with IC50s ranging from high to low micromolar. Androgen receptor (AR)-expressing cell lines MDA-MB-453 (triple negative breast cancer cell line) and LNCaP (prostate cancer cell line) are more cytotoxic to PQ (Table 1, Figure S1). Others have shown evidence of cell-line-dependent cytotoxic effects of PQ [15,24]. Compared to PQ, PQ-IAA 1 is slightly more cytotoxic to most of the tested cell lines except for LNCaP and MDA-MB-253 cells. Interestingly, the IAA/PQ combination showed attenuated cytotoxicity against most of the tested cell lines, relative to PQ, except for MCF-7. Unlike PQ, the IAA/PQ combination is not toxic against LNCaP, although MDA-MB-453 is the most responsive cell line to this combination (Table 1). Informed by this disparity in the pattern of cell toxicity of PQ, PQ-IAA 1, and the IAA/PQ combination, which seemed to favor PQ-IAA 1, we synthesized and probed the antiproliferative effects of PQ–indole carboxamide conjugates 2–7 incorporating other indole acid analogs. We first investigated carboxamides derived from three unmodified indole carboxylic acids: ICA, IPA, and indole-4-butyric acid (IBA). Among these carboxamides, the ICA-derived compound 2 elicited the most potent, cancer-cell-selective antiproliferative effect, being more potent than PQ and 1 against all tested cancer cell lines. An exception is MDA-MB-453, against which 2 is about 1.7-fold less potent compared to PQ. Of the tested cell lines, LNCaP is the most sensitive to 2, in a similar manner to the effect of PQ on this cell line. Also, we observed that 2 is more cytotoxic than the combination of ICA and PQ (Table 1). Subsequent modifications to the indole moiety on IAA and IPA did not translate to the enhancement of potency of the resulting compounds 3–7. Moreover, we synthesized and tested the antiproliferative activities of the enantiomers of 2 (compounds 8 and 10) and 4 (compounds 9 and 11). Surprisingly, and due to reasons unclear to us, the enantiomerically pure PQ and compounds 8–11 were less active than their corresponding racemic compounds 2 and 4. Racemic mixtures reconstituted from 8 and 10 and 9 and 11 elicited antiproliferative effects that nearly paralleled those of the corresponding compounds 2 and 4, respectively (Table 2, Figure S2).
Intrigued by the LNCaP cell preference of PQ and 2, we performed in silico docking using Autodock Vina (version 1.1.2) [25] to investigate the possibility of interaction of PQ, indole carboxylic acids, and representative indole carboxamides with AR, a nuclear receptor that is vital to the viability of LNCaP [26]. We conducted the molecular docking analysis at the AR ligand binding domain (LBD) [21] and binding function 3 (BF3) sites [22] using the R- and S-enantiomers of the disclosed PQ–indole compounds to obtain evidence for the involvement of AR interaction in their antiproliferative activities. Molecular docking predictions suggested that PQ–indole compounds are better accommodated at the AR-LBD (Figure S3, Tables S1 and S2). However, evaluation of selected PQ–indole compounds in a cell-free AR binding assay revealed that they lacked AR-binding activity (Figure S4).

2.3. Primaquine–Indole Carboxamide Generates Reactive Oxygen Species

The sustained proliferation, survival, and migration of cancer cells is dependent on the availability of relatively higher ROS levels in comparison to normal cells. However, ROS levels beyond a certain threshold can result in the induction of cancer cell death [27]. Since PQ is known to induce ROS in cells through the cycling of its hydroxylated metabolites [10,11,12,13,28], we probed for the ROS-inducing effects of 2, ICA, PQ, and the ICA/PQ combination in LNCaP using hydrogen peroxide as a positive control. As shown in Figure 2, PQ, at a concentration of 50 µM, caused a significant induction of ROS, as previously reported [28]. Similarly, hydrogen peroxide also induced ROS in LNCaP cells at 50 µM [29]. Interestingly, we observed that 2 is a much more effective ROS inducer, generating higher levels of ROS in LNCaP cells when compared with hydrogen peroxide, ICA, PQ, and the ICA/PQ combination. The efficiency of ROS induction by 2 could partly explain its enhanced antiproliferative activities relative to PQ.

2.4. Cell Cycle Progression Is Modulated by Primaquine-Indole Carboxamide

Finally, we determined the effects of 2 on cell cycle progression. Progression through the cell cycle is normally regulated to ensure that cells with DNA damage are repaired before progressing to the next phase; however, if the damage is beyond repair, such cells are eliminated via programmed cell death mechanisms, such as apoptosis [30]. In the case of cancer cells, to allow for cellular proliferation, some cell cycle checkpoints are dysfunctional [31], and if there is an approach to halt progression through the cell cycle, then the possibility of inducing apoptosis increases. We observed that LNCaP cells were dose-dependently and significantly arrested by 2 at both S and G2/M phases (Figure 3), with the S-phase cell cycle arrest being more relevant at the highest concentration while the G2/M phase reverts to control levels.

3. Materials and Methods

3.1. Chemicals, Synthesis, and Charaterization

Anhydrous solvents and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), Acros, VWR International (Radnor, PA, USA), or Thermo Fisher Scientific (Waltham, MA, USA) and were used without further purification. Analtech silica gel plates (60 F254, Miles Scientific, Newark, DE, USA) were utilized for analytical TLC, and Analtech preparative TLC plates (UV254, 2000 μm) [60 F254, Miles Scientific, Newark, DE, USA] were used for purification. Silica gel (200−400 mesh) was used in column chromatography. TLC plates were visualized using UV light, anisaldehyde, and iodine stains. NMR spectra were obtained on a Varian-Gemini 400 MHz and 700 MHz magnetic resonance spectrometer (Palo Alto, CA, USA). 1H NMR spectra were recorded in parts per million (ppm) relative to the residual peaks of CHCl3 (7.24 ppm) in CDCl3 or CHD2OD (4.78 ppm) in CD3OD or DMSO-d5 (2.49 ppm) in DMSO-d6. 13C spectra were recorded relative to the solvent’s peaks with complete hetero decoupling. MestReNova (version 11.0) was used to process the original NMR “fid” files. High-resolution mass spectra were recorded at Georgia Institute of Technology’s Systems Mass Spectrometry Core facility.

3.2. Molecular Docking Study

Energy minimization of all structures was performed in ChemDraw 3D (Version 23.1). A previously reported AR homology model (PDB: 2AM9) was utilized to investigate binding to the AR-LBD [1]. In addition, another AR structure (PDB: 4HLW) was used to assess binding at the BF3 site. Molecular docking computations were conducted through AutoDock Vina via PyRx (Version 0.8), and the subsequent outputs were analyzed and imaged in PyMol (Version 2.6).

3.3. Cell Culture

Hep-G2 and DU-145 cancer cell lines were cultured in MEM (Corning, Glendale, AZ, USA) with 10% FBS. MCF-7 cells were cultured in 10% FBS DMEM without phenol red; MDA-MB-231 and Vero cells were cultured in DMEM (Corning, Glendale, AZ, USA) with phenol red, while LNCaP cells were cultured using RPMI-1640 supplemented with 10% FBS. All cell lines used were derived from American Type Culture Collection.

3.4. MTS Cell Viability Assay

Cells were plated into a 96-well plate at a density of 4500 cells/100 µL and allowed to adhere for 24 h prior to treatment. Subsequently, cells were exposed to varying concentrations of drugs for 72 h. All drug solutions were prepared in DMSO/DMEM, maintaining a DMSO concentration of 1%. The impact of these compounds on cell viability was assessed using the MTS assay, employing CellTiter 96 Aqueous One Solution from Promega (Madison, WI, USA), following the manufacturer’s instructions. IC50 values were determined using Prism GraphPad 8.

3.5. Quantification of Reactive Oxygen Species

This analysis was carried out based on the manufacturer’s instructions (Canvax Biotech, S.L., Valladolid, Spain) with some modifications. LNCaP cells (0.5 × 106) were seeded in a 6-well plate for 24 h to allow cells to adhere. H2DCF-DA probe (15 µM final concentration) was added during treatment and incubated for 1 h. The cells were washed twice with 1 mL of ice-cold 1X phosphate-buffered saline (Corning, Glendale, AZ, USA), trypsinized, and the resulting cell suspension was transferred to microcentrifuge tubes. The cells were then centrifuged at 500× g for 5 min, after which the supernatant was carefully aspirated and discarded. For flow cytometry analysis, the tubes containing the stained cells were resuspended in 200 μL of growth medium and subsequently placed on ice. DCF fluorescence was detected by FACS, data were processed using FlowJo software, and the mean DCF fluorescence intensities were computed.

3.6. Cell Cycle Analysis

This analysis was carried out based on the manufacturer’s instructions (Canvax Biotech, S.L., Valladolid, Spain), also with some modifications. Briefly, cells (1 × 106 cells/well in 2 mL of medium) were seeded in six-well plates and allowed to attach for 24 h before treatment for another 24 h. Subsequently, cells were dissociated from the substrate using a cell scraper (Avantor Inc., Radnor, PA, USA), and the cell suspension was centrifuged at 500× g for 5 min at 4 °C with the supernatant aspirated and discarded. Cells were then washed in 1 mL ice-cold PBS and centrifuged again with the supernatant aspirated and discarded. Next, nucleic acid labeling was initiated by initially fixing the cells with 1 mL of ice-cold 70% ethanol added dropwise to the cell pellet while vortexing, and the samples were stored on ice for at least 30 min. Thereafter, without disrupting the pellet, ethanol was carefully removed by centrifugation at 2500× g for 5 min at 4 °C, and the cells were subsequently washed in 1 mL PBS. Again, PBS was removed by centrifugation at 2500× g for 5 min, and then the cells were resuspended with 200 μL of the staining solution (freshly prepared by mixing PBS with propidium iodide and RNase A in a ratio of 50:1:1, respectively), which should be protected from exposure to light. In preparation for flow cytometry analysis (using CytoFLEX S Flow Cytometer (CytExpert v2.4), Beckman Coulter Life Sciences, Indianapolis, IN, USA), the tubes containing the stained cells were incubated in the dark for 30 min at 37 °C and finally placed on ice before analysis.

3.7. AR-Binding Assay

The androgen receptor competitive binding of compound 2 was assessed using the PolarScreen Androgen Receptor Competitor Assay Kit, Green (#A15880, Thermo Fisher Scientific Inc., Carlsbad, CA, USA), based on the manufacturer’s instructions.

4. Conclusions

Overall, while molecular docking analyses originally implicated the androgen receptor (AR), we showed in this study that PQ–indole carboxamides possess promising antiproliferative activities, but not by AR engagements based on negligible AR cell-free binding affinities. Our data revealed that compound 2, the most potent among the PQ–indole carboxamides disclosed herein, derived a significant part of its antiproliferative effect from ROS generation. However, the mechanism(s) of ROS generation activity of 2 is yet to be elucidated.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules30193988/s1, Figure S1: Dose–response curves of the antiproliferative effects of the primaquine (PQ, a) and PQ–indole carboxamides (b–h) against the tested cell lines; Figure S2: Dose–response curves of the antiproliferative effects of the enantiomerically pure compounds 8–11 and racemic mixtures reconstituted from 8 and 10 and 9 and 11 against the tested cell lines; Figure S3: Images from molecular docking study of potential interaction of PQ–indole carboxamide with AR. (A) Docked indole moiety (in yellow; −6.2 kcal/mol) positioned next to the docked output of S-PQ (white; −4.7 kcal/mol). Note the overlap between the amine of primaquine and the amide of the indole moiety. (B) Docked orientation of 2R (−8.6 kcal/mol) within the AR-LBD. The potential for hydrogen bonding between Met-74 and Thr-209 is detailed. (C) Docked output of 1S (−6.9 kcal/mol) within the BF3 Site of AR (PDB: 4HLW). Hydrogen bonding was observed with Glu-837; Figure S4: Dose–response curves of the AR binding affinity of the PQ–indole carboxamides; Table S1: Docked scores of the PQ–indole carboxamides at AR-LBD compared to antiandrogen enzalutamide. Table S2: Docked scores of the PQ–indole carboxamides at the BF3 site compared to VPC-13789, an established AR-BF3 site binder.

Author Contributions

Conceptualization, A.K.O.; methodology, B.H.P., J.O.O. and D.T.W.; validation, J.O.O. and D.T.W.; formal analysis, J.O.O., D.T.W. and A.K.O.; investigation, B.H.P., J.O.O. and D.T.W.; resources, A.K.O.; data curation, B.H.P., J.O.O. and D.T.W.; writing—original draft, B.H.P., J.O.O., D.T.W. and A.K.O.; writing—review and editing, B.H.P., J.O.O., D.T.W. and A.K.O.; supervision, A.K.O.; funding acquisition, A.K.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by NIH, grant numbers R01CA252720 and R01CA266013.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Acknowledgments

B.H.P. was supported by the President’s Undergraduate Research Award (PURA) from Georgia Tech.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

PQPrimaquine
ICAindole-3-carboxylic acid
IAAindole-3-acetic acid
IPAindole-3-propionic acid
IBAindole-4-butyric acid
ARandrogen receptor
LBDligand binding domain
BF3binding function 3

References

  1. Sinha, A.K.; Laursen, M.F.; Brinck, J.E.; Rybtke, M.L.; Hjørne, A.P.; Procházková, N.; Pedersen, M.; Roager, H.M.; Licht, T.R. Dietary fibre directs microbial tryptophan metabolism via metabolic interactions in the gut microbiota. Nat. Microbiol. 2024, 9, 1964–1978. [Google Scholar] [CrossRef]
  2. Roager, H.M.; Licht, T.R. Microbial tryptophan catabolites in health and disease. Nat. Commun. 2018, 9, 3294. [Google Scholar] [CrossRef]
  3. Jia, D.; Kuang, Z.; Wang, L. The role of microbial indole metabolites in tumor. Gut Microbes 2024, 16, 2409209. [Google Scholar] [CrossRef] [PubMed]
  4. Tintelnot, J.; Xu, Y.; Lesker, T.R.; Schönlein, M.; Konczalla, L.; Giannou, A.D.; Pelczar, P.; Kylies, D.; Puelles, V.G.; Bielecka, A.A.; et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 2023, 615, 168–174. [Google Scholar] [CrossRef]
  5. Folkes, L.K.; Dennis, M.F.; Stratford, M.R.; Candeias, L.P.; Wardman, P. Peroxidase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro. Biochem. Pharmacol. 1999, 57, 375–382. [Google Scholar] [CrossRef] [PubMed]
  6. Folkes, L.K.; Wardman, P. Oxidative activation of indole-3-acetic acids to cytotoxic species- a potential new role for plant auxins in cancer therapy. Biochem. Pharmacol. 2001, 61, 129–136. [Google Scholar] [CrossRef]
  7. Folkes, L.K.; Wardman, P. Enhancing the efficacy of photodynamic cancer therapy by radicals from plant auxin (indole-3-acetic acid). Cancer Res. 2003, 63, 776–779. [Google Scholar]
  8. Kim, S.Y.; Ryu, J.S.; Li, H.; Park, W.-J.; Yun, H.-Y.; Baek, K.J.; Kwon, N.S.; Sohn, U.D.; Kim, D.-S. UVB-activated indole-3-acetic acid induces apoptosis of PC-3 prostate cancer cells. Anticancer Res. 2010, 30, 4607–4612. [Google Scholar] [PubMed]
  9. Diengott, D.; Mirsky, I.A. Hypoglycemic action of indole-3-acetic acid by mouth in patients with diabetes mellitus. Proc. Soc. Exp. Biol. Med. 1956, 93, 109–110. [Google Scholar]
  10. Vasquez-Vivar, J.; Augusto, O. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J. Biol. Chem. 1992, 267, 6848–6854. [Google Scholar] [CrossRef]
  11. Pybus, B.S.; Marcsisin, S.R.; Jin, X.; Deye, G.; Sousa, J.C.; Li, Q.; Caridha, D.; Zeng, Q.; Reichard, G.A.; Ockenhouse, C.; et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar. J. 2013, 12, 212. [Google Scholar] [CrossRef] [PubMed]
  12. Camarda, G.; Jirawatcharadech, P.; Priestley, R.S.; Saif, A.; March, S.; Wong, M.H.L.; Leung, S.; Miller, A.B.; Baker, D.A.; Alano, P.; et al. Antimalarial activity of primaquine operates via a two-step biochemical relay. Nat. Commun. 2019, 10, 3226. [Google Scholar] [CrossRef]
  13. Marcsisin, S.R.; Reichard, G.; Pybus, B.S. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art. Pharmacol. Ther. 2016, 161, 1–10. [Google Scholar] [CrossRef] [PubMed]
  14. Kim, J.H.; Choi, H.S.; Lee, D.S. Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation. Int. J. Mol. Sci. 2021, 22, 12961. [Google Scholar] [CrossRef]
  15. Pavic, K.; Rubinic, B.; Rajic, Z.; Fontinha, D.; Prudêncio, M.; Uzelac, L.; Kralj, M.; Held, J.; Zorc, B. Primaquine homodimers as potential antiplasmodial and anticancer agents. Bioorg. Med. Chem. Lett. 2019, 29, 126614. [Google Scholar] [CrossRef]
  16. Duarte, D.; Vale, N. New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells. Biomolecules 2020, 10, 1623. [Google Scholar] [CrossRef]
  17. Nordor, A.V.; Bellet, D.; Siwo, G.H. Cancer-malaria: Hidden connections. Open Biol. 2018, 8, 180127. [Google Scholar] [CrossRef]
  18. Qin, L.; Chen, C.; Chen, L.; Xue, R.; Ou-Yang, M.; Zhou, C.; Zhao, S.; He, Z.; Xia, Y.; He, J.; et al. Worldwide malaria incidence and cancer mortality are inversely associated. Infect. Agents Cancer 2017, 12, 14. [Google Scholar] [CrossRef]
  19. Kim, J.H.; Choi, A.R.; Kim, Y.K.; Yoon, S. Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition. Biochem. Biophys. Res. Commun. 2013, 441, 655–660. [Google Scholar] [CrossRef] [PubMed]
  20. Choi, A.R.; Kim, J.H.; Woo, Y.H.; Kim, H.S.; Yoon, S. Anti-malarial Drugs Primaquine and Chloroquine Have Different Sensitization Effects with Anti-mitotic Drugs in Resistant Cancer Cells. Anticancer Res. 2016, 36, 1641–1648. [Google Scholar] [CrossRef]
  21. Gryder, B.E.; Akbashev, M.J.; Rood, M.K.; Raftery, E.D.; Meyers, W.M.; Dillard, P.; Khan, S.; Oyelere, A.K. Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. ACS Chem. Biol. 2013, 8, 2550–2560. [Google Scholar] [CrossRef]
  22. Leblanc, E.; Ban, F.; Cavga, A.D.; Lawn, S.; Huang, C.-C.F.; Mohan, S.; Chang, M.E.K.; Flory, M.R.; Ghaidi, F.; Lingadahalli, S.; et al. Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. J. Med. Chem. 2021, 64, 14968–14982. [Google Scholar] [CrossRef]
  23. Nanayakkara, N.P.; Tekwani, B.L.; Herath, H.M.; Sahu, R.; Gettayacamin, M.; Tungtaeng, A.; van Gessel, Y.; Baresel, P.; Wickham, K.S.; Bartlett, M.S.; et al. Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers. Antimicrob. Agents Chemother. 2014, 58, 4737–4744. [Google Scholar] [CrossRef] [PubMed]
  24. Pavic, K.; Poje, G.; Pessanha de Carvalho, L.; Tandarić, T.; Marinović, M.; Fontinha, D.; Held, J.; Prudêncio, M.; Piantanida, I.; Vianello, R.; et al. Discovery of harmiprims, harmine-primaquine hybrids, as potent and selective anticancer and antimalarial compounds. Bioorg. Med. Chem. 2024, 105, 117734. [Google Scholar] [CrossRef]
  25. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef]
  26. Schiewer, M.J.; Augello, M.A.; Knudsen, K.E. The AR dependent cell cycle: Mechanisms and cancer relevance. Mol. Cell. Endocrinol. 2012, 352, 34–45. [Google Scholar] [CrossRef]
  27. Nakamura, H.; Takada, K. Reactive oxygen species in cancer: Current findings and future directions. Cancer Sci. 2021, 112, 3945–3952. [Google Scholar] [CrossRef] [PubMed]
  28. Ganesan, S.; Chaurasiya, N.D.; Sahu, R.; Walker, L.A.; Tekwani, B.L. Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: Evaluation of eryptotic pathway. Toxicology 2012, 294, 54–60. [Google Scholar] [CrossRef] [PubMed]
  29. Xin, X.; Gong, T.; Hong, Y. Hydrogen peroxide initiates oxidative stress and proteomic alterations in meningothelial cells. Sci. Rep. 2022, 12, 14519. [Google Scholar] [CrossRef]
  30. Manchado, E.; Guillamot, M.; Malumbres, M. Killing cells by targeting mitosis. Cell Death Differ. 2012, 19, 369–377. [Google Scholar] [CrossRef]
  31. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12, 801–817. [Google Scholar] [CrossRef] [PubMed]
Molecules 30 03988 g001
Figure 1. Structures of indole carboxylic acids derived from tryptophan metabolism and primaquine.
Figure 1. Structures of indole carboxylic acids derived from tryptophan metabolism and primaquine.
Molecules 30 03988 g001
Molecules 30 03988 sch001
Scheme 1. Synthesis of PQ–indole carboxamides 1–7. Reagents and conditions: (a) EDCI.HCl, DMAP, CH2Cl2, rt, 15 h; (b) LiOH, THF: MeOH: H2O, rt, 15 h.
Scheme 1. Synthesis of PQ–indole carboxamides 1–7. Reagents and conditions: (a) EDCI.HCl, DMAP, CH2Cl2, rt, 15 h; (b) LiOH, THF: MeOH: H2O, rt, 15 h.
Molecules 30 03988 sch001
Molecules 30 03988 sch002aMolecules 30 03988 sch002b
Scheme 2. Synthesis of enantiomerically pure PQ–indole carboxamides 8–11. Reagents and conditions: (a) EDCI.HCl, DMAP, CH2Cl2, rt, 15 h.
Scheme 2. Synthesis of enantiomerically pure PQ–indole carboxamides 8–11. Reagents and conditions: (a) EDCI.HCl, DMAP, CH2Cl2, rt, 15 h.
Molecules 30 03988 sch002aMolecules 30 03988 sch002b
Molecules 30 03988 g002
Figure 2. Changes in intracellular ROS levels, induced by the test agents, were measured in LNCaP cells, treated for 1 h, using DCFH-DA and flow cytometric analysis. Histogram representation of the fluorescence intensities of ROS levels in DMSO-treated cells in comparison with cells treated with 50 µM of hydrogen peroxide (H2O2, (a)), indole-3-carboxylic acid (ICA, (b)), primaquine (PQ, (c)), ICA/PQ (d), and 2 ((e,f), at 25 and 50 µM, respectively) along with their quantifications (g). * p < 0.05; ** p < 0.01; **** p < 0.0001.
Figure 2. Changes in intracellular ROS levels, induced by the test agents, were measured in LNCaP cells, treated for 1 h, using DCFH-DA and flow cytometric analysis. Histogram representation of the fluorescence intensities of ROS levels in DMSO-treated cells in comparison with cells treated with 50 µM of hydrogen peroxide (H2O2, (a)), indole-3-carboxylic acid (ICA, (b)), primaquine (PQ, (c)), ICA/PQ (d), and 2 ((e,f), at 25 and 50 µM, respectively) along with their quantifications (g). * p < 0.05; ** p < 0.01; **** p < 0.0001.
Molecules 30 03988 g002
Molecules 30 03988 g003
Figure 3. Modulation of cell cycle progression by compound 2 in LNCaP cells. Cell cycle distribution of both untreated (a) and treated (b–d) LNCaP cells was assessed by flow cytometric analysis. Unsynchronized LNCaP cells were treated with 2 for 24 h, subjected to PI/RNase staining, and the data obtained were analyzed by the Dean–Jett–Fox model using FlowJo software v. 10. From the distribution profiles (e–g), 2 caused a significant increase in accumulation of cells in both S and G2/M phases. The G2/M phase of 2 at 2×IC50 was manually adjusted. ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Figure 3. Modulation of cell cycle progression by compound 2 in LNCaP cells. Cell cycle distribution of both untreated (a) and treated (b–d) LNCaP cells was assessed by flow cytometric analysis. Unsynchronized LNCaP cells were treated with 2 for 24 h, subjected to PI/RNase staining, and the data obtained were analyzed by the Dean–Jett–Fox model using FlowJo software v. 10. From the distribution profiles (e–g), 2 caused a significant increase in accumulation of cells in both S and G2/M phases. The G2/M phase of 2 at 2×IC50 was manually adjusted. ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Molecules 30 03988 g003
Table 1. Antiproliferative activities of primaquine–indole carboxamides.
Table 1. Antiproliferative activities of primaquine–indole carboxamides.
StructureIC50 (µM)
DU-145LNCaPHep-G2MCF-7MDA-MB-231MDA-MB-453Vero
Molecules 30 03988 i001>100>100>100>100>100>100>100
Molecules 30 03988 i002>100>100>100>100>100>100>100
Molecules 30 03988 i00397.20 ± 5.629.50 ± 6.571.40 ± 12.490.92 ± 8.965.42 ± 2.313.72 ± 3.287. 55 ± 21.6
ICA + PQ35.9740.73 ± 1.182.57NTNTNTNT
IAA + PQ>100>10082.65 ± 17.040.40 ± 8.544.94 ± 2.226.78 ± 5.7>100
Molecules 30 03988 i00446.43 ± 9.348.67 ± 10.148.77 ± 1.348.27 ± 4.057.8942.53 ± 2.5 91.50 ± 12.0
Molecules 30 03988 i00514.75 ± 3.811.90 ± 4.734.41 ± 4.343.68 ± 7.638.74 ± 3.423.83 ± 2.682.55 ± 15.7
Molecules 30 03988 i00656.26 ± 11.733.47 ± 5.332.22 ± 1.667.10 ± 6.699.52 ± 1.6 43.54 ± 5.2 >100
Molecules 30 03988 i00767.69 ± 11.025.93 ± 4.782.56 ± 13.190.55 ± 16.4>10030.41 ± 8.2>100
Molecules 30 03988 i00837.71 ± 4.032.90 ± 9.58 29.40 ± 10.042.51 ± 4.4>100.0033.57 ± 0.09 >100
Molecules 30 03988 i009>100>100>100>100>100>100>100
Molecules 30 03988 i01040.17 ± 4.024.28 ± 4.743.87 ± 3.848.77 ± 10.945.83 ± 5.136.20 ± 1.0 83.42 ± 2.3
Enzalutamide21.26 ± 1.555.55 ± 7.9>100>100>10074.33 ± 22.7 >100
NT: not tested.
Table 2. Antiproliferative activities of enantiomerically pure PQ-carboxamides 8–11.
Table 2. Antiproliferative activities of enantiomerically pure PQ-carboxamides 8–11.
StructureIC50 (µM)
DU-145LNCaPHep-G2MCF-7MDA-MB-231MDA-MB-453Vero
Molecules 30 03988 i011>100>100>100>10056.22 ± 7.123.45 ± 1.5>100
Molecules 30 03988 i012>100>100>100>100 87.50 ± 12.528.19 ± 1.3>100
(+)-(S)-PQ + (-)-(R)-PQ41.3752.3957.95 ± 0.145.31 ± 5.5 38.46 ± 9.921.45 ± 2.6>100
Molecules 30 03988 i01335.56 ± 1.840.38 ± 7.052.0794.21 ± 5.053.09 ± 1.838.47 ± 4.6>100
Molecules 30 03988 i01437.89 ± 2.532.09 ± 3.847.99 ± 2.778.51 ± 6.151.06 ± 4.7 16.06 ± 3.0>100
8 + 1025.15 ± 8.818.83 ± 1.729.96 ± 5.937.45 ± 8.826.31 ± 1.0 17.79 ± 0.9>100
Molecules 30 03988 i01591.75 ± 11.724.75 ± 0.364.82 ± 5.699.72 ± 0.4>10031.82 ± 2.9>100
Molecules 30 03988 i01665.81 ± 5.421.29 ± 5.543.22 ± 2.698.50 ± 2.1>10019.30 ± 0.9>100
9 + 1149.80 ± 8.58.83 ± 2.026.90 ± 1.5>50>50 12.14 ± 0.8>100
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Peer, B.H.; Olugbami, J.O.; Walunj, D.T.; Oyelere, A.K. Discovery of Primaquine–Indole Carboxamides with Cancer-Cell-Selective Antiproliferative Activity. Molecules 2025, 30, 3988. https://doi.org/10.3390/molecules30193988

AMA Style

Peer BH, Olugbami JO, Walunj DT, Oyelere AK. Discovery of Primaquine–Indole Carboxamides with Cancer-Cell-Selective Antiproliferative Activity. Molecules. 2025; 30(19):3988. https://doi.org/10.3390/molecules30193988

Chicago/Turabian Style

Peer, Benjamin H., Jeremiah O. Olugbami, Dipak T. Walunj, and Adegboyega K. Oyelere. 2025. "Discovery of Primaquine–Indole Carboxamides with Cancer-Cell-Selective Antiproliferative Activity" Molecules 30, no. 19: 3988. https://doi.org/10.3390/molecules30193988

APA Style

Peer, B. H., Olugbami, J. O., Walunj, D. T., & Oyelere, A. K. (2025). Discovery of Primaquine–Indole Carboxamides with Cancer-Cell-Selective Antiproliferative Activity. Molecules, 30(19), 3988. https://doi.org/10.3390/molecules30193988

Article Metrics

Back to TopTop